Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 6/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10625450 | 0.87 | TRPA1 (0.49) | TRPA1RAPGEF4CYP1A2THRB | |
| SCHEMBL10345191 | 0.85 | CA12 (0.46) | TRPA1CYP1A2IDO1 | |
| SCHEMBL6233796 | 0.84 | KCNH3 (0.47) | — | |
| SCHEMBL3959091 | 0.82 | RAPGEF4 (0.40) | TRPA1RAPGEF4CYP1A2IDO1 | |
| SCHEMBL13736518 | 0.80 | PGR (0.39) | THRB | |
| Hydrochloric Acid SCHEMBL13736778 | 0.80 | IDO1 (0.37) | TRPA1CYP1A2IDO1 | |
| SCHEMBL6235610 | 0.78 | MAPT (0.50) | TRPA1RAPGEF4CYP1A2IDO1 | |
| SCHEMBL30045340 | 0.77 | IDO1 (0.36) | RAPGEF4IDO1 | |
| SCHEMBL25650262 | 0.76 | RAPGEF4 (0.41) | TRPA1RAPGEF4CYP1A2MAPK1CHRNA7 | |
| Hydrochloric Acid SCHEMBL5857094 | 0.76 | MAPT (0.48) | TRPA1RAPGEF4CYP1A2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-11-12 | — | — | US | disclosed |
| EP-1530562-A1 | OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME | Central Glass Company, Limited (JP) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004022521-A1 | OPTICALLY ACTIVE 1-(FLUORO-,TRIFLUOROMETHYL-OR TRIFLUOROMETHOXY-SUBSTITUTED PHENYL)ALKYLAMINE N-MONOALKYL DERIVATIVES AND PROCESS FOR PRODUCING SAME | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472315-B2 | Inhibitors of methionine aminopeptidases and methods of treating disorders | METAP1, METAP2, ENPEP | TRPA1 4410/4885RAPGEF4 4734/4885CYP1A2 1045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.